Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

April 20, 2007 08:30 ET

Stem Cell Therapeutics Corp. Announces Presentations at EQUITIES Magazine 56th Anniversary Spring Conference & BioFinance

CALGARY, ALBERTA--(CCNMatthews - April 20, 2007) - Stem Cell Therapeutics Corp. ("SCT")(TSX VENTURE:SSS) announces that Dr. Alan Moore, President and CEO, will be presenting today at the EQUITIES Magazine's 56th Anniversary Spring Conference held at the Yale Club in New York, New York; as well as the BioFinance 2007 Conference to be held at the Marriott Eaton Centre in Toronto April 24-26, 2007.

Dr. Alan Moore will provide an overview to industry executives, potential collaborators, and investors, regarding SCT's Phase IIa clinical safety study with NTx™-265 in stroke victims as well as outline the company's future goals and planned clinical programs.

About EQUITIES Magazine ( ): EQUITIES Magazine corporate conferences bring together executives and corporate and institutional investment professionals who closely follow and invest in mid cap and small cap growth companies. EQUITIES magazine corporate conferences now celebrate 25 years of bridging the gap between emerging public companies and the investment community.

About BioFinance ( ): BioFinance 2007 is the Canadian Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia.

About NTx™-265: NTx™-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. Human chorionic gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke. Animal studies have shown a significant recovery in motor function in animals that have been given a stroke and subsequently been treated with the NTx™-265 therapy. Currently, SCT is enrolling patients in a phase IIa clinical trial in the United States in order to investigate the safety and efficacy of NTx™-265 in humans.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. SCT's currently enrolling phase IIa clinical program for NTx™-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information